Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips

Authors:
Sayaka Deguchi , Kaori Kosugi , Rina Hashimoto, Ayaka Sakamoto , Masaki Yamamoto, Rafal P Krol, Peter Gee , Ryosuke Negoro , Takeshi Noda , Takuya Yamamoto , Yu-Suke Torisawa , Miki Nagao , Kazuo Takayama 
In:
Source: Proc Natl Acad Sci USA
Publication Date: (2023)
Issue: 2: 3
Research Area:
Gastroenterology
Cells used in publication:
Endothelial, umbilical vein, human (HUVEC)
Species: human
Tissue Origin: vein
Hepatocyte, human
Species: human
Tissue Origin: liver
Experiment

Cell culture

Before seeding cholangiocytes or endothelial cells, a bottom channel of the PDMS device was pre-coated with fibronectin (1 µg/mL, Sigma-Aldrich). Cholangiocytes (HuCCT1 cells, JCRB0425, JCRB Cell Bank) or endothelial cells (Human Umbilical Vein Endothelial Cells: HUVECs, Lonza) were suspended at 5 × 106 cells/mL in RPMI-1640 medium containing 1×GlutaMAX (Thermo Fisher Scientific) and 10% fetal bovine serum (FBS) or EGM-2 Endothelial Cell Growth Medium-2 BulletKit (Lonza), respectively. Ten µL suspension medium was injected into the fibronectin-coated bottom channel. Then, the device was turned upside down and incubated for 1 h. After the incubation, the device was turned over, and the medium was injected into the bottom channel.

After 4 days, human hepatocytes (HUCPI, Lonza) were seeded into the top channel. Before seeding hepatocytes, the PDMS devices were pre-coated with Collagen I solution (30 µg/mL, Corning). The vials of human hepatocytes were rapidly thawed in a shaking water bath at 37°C. The contents of each vial were emptied into pre-warmed Cryopreserved Hepatocyte Recovery Medium (Thermo Fisher Scientific), and the suspension was centrifuged at 1,200 rpm for 5 min at room temperature. Hepatocytes were suspended at 5 × 106 cells/mL in Hepatocyte Culture Medium BulletKit (HCM, Lonza) containing 10% FBS. Ten µL suspension medium was injected into a Collagen Type I (Corning)-coated PDMS device. After 1 h, the medium was added into the top and bottom channels.

Abstract

SARS-CoV-2 induces severe organ damage not only in the lung but also in the liver, heart, kidney, and intestine. It is known that COVID-19 severity correlates with liver dysfunction, but few studies have investigated the liver pathophysiology in COVID-19 patients. Here, we elucidated liver pathophysiology in COVID-19 patients using organs-on-a-chip technology and clinical analyses. First, we developed liver-on-a-chip (LoC) which recapitulating hepatic functions around the intrahepatic bile duct and blood vessel. We found that hepatic dysfunctions, but not hepatobiliary diseases, were strongly induced by SARS-CoV-2 infection. Next, we evaluated the therapeutic effects of COVID-19 drugs to inhibit viral replication and recover hepatic dysfunctions, and found that the combination of anti-viral and immunosuppressive drugs (Remdesivir and Baricitinib) is effective to treat hepatic dysfunctions caused by SARS-CoV-2 infection. Finally, we analyzed the sera obtained from COVID-19 patients, and revealed that COVID-19 patients, who were positive for serum viral RNA, are likely to become severe and develop hepatic dysfunctions, as compared with COVID-19 patients who were negative for serum viral RNA. We succeeded in modeling the liver pathophysiology of COVID-19 patients using LoC technology and clinical samples.